RxDoctor Payments Data

Rajesh Chandwaney, MD

Interventional Cardiology · Tulsa, OKNPI 1174593461

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,900 of the $3,238 with a category attached, or 89.6%. 14 manufacturers reported payments, led by Boston Scientific at 25.2% of the total. 2025 is the largest year on record at $1,076, 2.5 times the $425 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in OK, where the typical reported total is $7,360.

$3,238in general payments, 2019–2025

Across 57 payments — averaging $56.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$817
  • Medtronic$681
  • Abiomed$499
  • Abbott$267
  • Recor Medical Inc$239
  • W. L. Gore & Associates, Inc.$193
  • plus $543 from 8 others
$10,250in research payments, 2019–2025

Across 7 payments — averaging $1464.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$10K

What the payments were for

  • Travel & lodging$2327%
  • Food & beverage$2,90090%
  • Education$1063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,238 in reported general payments places this provider in the 30th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$153,830
Medicare patients
446
Services billed
1,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$125,094
EntrestoSacubitril/Valsartan114$104,334
Repatha SureclickEvolocumab54$58,330
BrilintaTicagrelor68$48,133
XareltoRivaroxaban25$26,170
ClopidogrelClopidogrel Bisulfate702$8,564
Rosuvastatin Calcium377$7,770
Ranolazine ErRanolazine113$7,179
Atorvastatin Calcium556$6,834
Metoprolol Succinate488$5,067
Ezetimibe177$4,099
Isosorbide Mononitrate ErIsosorbide Mononitrate463$3,306
Prasugrel Hcl24$2,790
Diltiazem 12hr ErDiltiazem Hcl12$2,319
Potassium Chloride135$1,676

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →